POLE and colorectal carcinoma: In stage II/III CRC patients with RFS information from the TCGA‐COAD/READ cohort, about 80% (4/5) of patients with POLE mutations were MSI‐H, whereas about 20% (1/5) of patients with POLE mutations were MSS.